loading
Precedente Chiudi:
$0.5266
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$1.56M
Reddito:
-
Utile/perdita netta:
$-34.58M
Rapporto P/E:
0.00
EPS:
-11.69
Flusso di cassa netto:
$-26.63M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
Value
$0.00
$0.00
Intervallo di 1 settimana:
Value
$0.00
$0.00
Portata 52W:
Value
$0.00
$10.61

Oncternal Therapeutics Inc Stock (ONCT) Company Profile

Name
Nome
Oncternal Therapeutics Inc
Name
Telefono
(858) 434-1113
Name
Indirizzo
12230 EL CAMINO REAL, SAN DIEGO, CA
Name
Dipendente
27
Name
Cinguettio
@oncternal
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
ONCT's Discussions on Twitter

Confronta ONCT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ONCT
Oncternal Therapeutics Inc
0.00 1.56M 0 -34.58M -26.63M -11.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
488.04 125.43B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
715.85 76.60B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
667.95 39.57B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
274.45 35.33B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
122.10 28.08B 3.30B -501.07M 1.03B -2.1146

Oncternal Therapeutics Inc Stock (ONCT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-04-07 Iniziato Oppenheimer Outperform
2021-02-23 Iniziato Northland Capital Outperform

Oncternal Therapeutics Inc Borsa (ONCT) Ultime notizie

pulisher
Feb 03, 2025

Head-To-Head Survey: Oncternal Therapeutics (NASDAQ:ONCT) & Organigram (NASDAQ:OGI) - Defense World

Feb 03, 2025
pulisher
Jan 30, 2025

Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com - Defense World

Jan 30, 2025
pulisher
Jan 24, 2025

Future-Proofing Growth of Metastatic Prostate Cancer Market, - openPR

Jan 24, 2025
pulisher
Jan 22, 2025

Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com - Defense World

Jan 22, 2025
pulisher
Jan 14, 2025

StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World

Jan 14, 2025
pulisher
Jan 07, 2025

B-cell Lymphoma Pipeline Update 2024: FDA Approvals, - openPR

Jan 07, 2025
pulisher
Jan 06, 2025

Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com - Defense World

Jan 06, 2025
pulisher
Dec 29, 2024

Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com - Defense World

Dec 29, 2024
pulisher
Dec 19, 2024

Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Marketscreener.com

Dec 19, 2024
pulisher
Dec 10, 2024

CELUCelularity Inc. Latest Stock News & Market Updates - StockTitan

Dec 10, 2024
pulisher
Dec 02, 2024

ONCT stock touches 52-week low at $0.61 amid market challenges - Investing.com Australia

Dec 02, 2024
pulisher
Dec 02, 2024

ONCT stock touches 52-week low at $0.61 amid market challenges By Investing.com - Investing.com South Africa

Dec 02, 2024
pulisher
Nov 27, 2024

StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World

Nov 27, 2024
pulisher
Nov 26, 2024

ONCT stock touches 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa

Nov 26, 2024
pulisher
Nov 25, 2024

ONCT stock touches 52-week low at $0.83 amid market challenges - Investing.com

Nov 25, 2024
pulisher
Nov 25, 2024

Oncternal shares to be delisted from Nasdaq - Investing.com

Nov 25, 2024
pulisher
Nov 20, 2024

Oncternal Therapeutics Reports Q3 2024 Earnings - TipRanks

Nov 20, 2024
pulisher
Nov 20, 2024

ONCT (Oncternal Therapeutics) 9-Day RSI : 33.20 (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 15, 2024

Oncternal announces workforce reduction, executive changes - Investing.com

Nov 15, 2024
pulisher
Nov 14, 2024

Oncternal Therapeutics to Cut Most of Its Workforce - MarketWatch

Nov 14, 2024
pulisher
Nov 14, 2024

Oncternal Therapeutics Announces Workforce Reduction and Executive Changes - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

ONCT Stock Touches 52-Week Low at $1.03 Amid Market Challenges - Investing.com

Nov 14, 2024
pulisher
Nov 07, 2024

Phase 1/2 trial of ONCT-534 in mCRPC has been terminated - Urology Times

Nov 07, 2024
pulisher
Oct 30, 2024

Oncternal Therapeutics, Inc. Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - Marketscreener.com

Oct 30, 2024
pulisher
Oct 23, 2024

Oncternal reports positive prostate cancer treatment results By Investing.com - Investing.com Australia

Oct 23, 2024
pulisher
Oct 22, 2024

Oncternal reports positive prostate cancer treatment results - Investing.com India

Oct 22, 2024
pulisher
Oct 22, 2024

Oncternal Therapeutics Announces Updated Safety and - GlobeNewswire

Oct 22, 2024
pulisher
Oct 18, 2024

B-Cell Non-Hodgkin Lymphoma Pipeline Assessment 2024: Therapies, Clinical Trials, and Growth Prospects | Biegene, Oncternal Therapeutics, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus - Barchart

Oct 18, 2024
pulisher
Oct 11, 2024

ONCT Stock Touches 52-Week Low at $1.19 Amid Market Challenges - Investing.com Australia

Oct 11, 2024
pulisher
Oct 09, 2024

Oncternal Therapeutics Inc (ONCT) Q2 2024 Earnings Call Highlights: Advancements in Clinical ... - Yahoo Finance Australia

Oct 09, 2024
pulisher
Oct 03, 2024

Oncternal stock jumps 9% on FDA fast track designation - MSN

Oct 03, 2024
pulisher
Oct 01, 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.58% - MSN

Oct 01, 2024
pulisher
Sep 30, 2024

ONCT Stock Touches 52-Week Low at $1.31 Amid Market Challenges - Investing.com Australia

Sep 30, 2024
pulisher
Sep 30, 2024

ONCT Stock Touches 52-Week Low at $1.31 Amid Market Challenges By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 27, 2024

Recent Research Analysts’ Ratings Changes for Oncternal Therapeutics (ONCT) - Defense World

Sep 27, 2024
pulisher
Sep 25, 2024

Omnicell Appoints Nnamdi Njoku as New COO - TipRanks

Sep 25, 2024
pulisher
Sep 25, 2024

Oncolytics Biotech (TSE:ONC) Reaches New 12-Month Low at $1.20 - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

ONON’s Stock Market Adventure: 85.15% YTD Growth Amidst Volatility - The InvestChronicle

Sep 25, 2024
pulisher
Sep 25, 2024

Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer - Silicon UK

Sep 25, 2024
pulisher
Sep 25, 2024

ONMD’s price-to-free cash flow ratio: How it affects investment decisions - US Post News

Sep 25, 2024
pulisher
Sep 25, 2024

Levi & Korsinsky Notifies Shareholders of Outset Medical, - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Outset Medical, Inc.OM - PR Newswire

Sep 25, 2024
pulisher
Sep 25, 2024

Fred Alger Management LLC Has $44.73 Million Position in On Holding AG (NYSE:ONON) - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace

Sep 25, 2024
pulisher
Sep 24, 2024

Recent Insider Activity Suggests Potential Gains for Outset Medical Inc (OM) - Knox Daily

Sep 24, 2024

Oncternal Therapeutics Inc Azioni (ONCT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$80.48
price down icon 0.51%
$21.12
price up icon 2.45%
$355.15
price up icon 0.72%
$5.04
price down icon 0.59%
biotechnology ONC
$228.37
price up icon 2.52%
$122.21
price up icon 4.33%
Capitalizzazione:     |  Volume (24 ore):